lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 1, 2026
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
May 1, 2026
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
April 30, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2026
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
April 28, 2026
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
March 9, 2026